Global Life Science Ventures — Investing in the life sciences

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.

Profile
Team
Investment Practice
Portfolio
FAQ
Download Area
News
Events
Contact Us
Text size

GLSV news

22.04.2008 GLSV receives 2007 Dyodelta European Life Science Innovation Award "Investor of the Year Award" more...

14.04.2008 April 2008 Teil 20 der Serie: Köpfe der deutschsprachigen Private Equity-Szene, Hanns-Peter Wiese, Venture Capial Magazin 4/2008 more...

17.01.2008 GLSV leads investment in Action Pharma A/S more...

06.12.2007 GLSV invests in Pelikan Technologies more...

02.10.2007 Biotech Investment Barometer Reveals Continued Confidence in Sector
more...

11.05.2007 NeurogesX Launches IPO on NASDAQ more...

29.03.2007 GLSV co-leads Series E investment in Coapt Systems more...

20.12.2006 "10 years' investing in the life sciences" more...

30.10.2006 GLSV Invests in Intelligent Medical Implants - Visual Prosthesis for the Blind more...

03.10.2006 GLSV Biotech Investment Barometer Reveals Continued Optimism
more...

More news

............................................................................................

Portfolio company news

27.11.2008 MediGene: European Patent Office decides to grant new European Patent for Veregen® more...

22.10.2008 NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN) more...

20.10.2008 MediGene Reports Positive Final Results from EndoTAG(TM)-1 Phase II Study in Pancreatic Cancer more...

17.10.2008 Medigene: RhuDex(TM) to be Examined in Further Laboratory Tests more...

15.10.2008 New class of drug candidates developed by Santaris Pharma can potently counteract disease-associated microRNAs more...

01.10.2008 MediGene Spins Out mTCR Programme - Independent Company Immunocore Limited Founded more...

29.09.2008 Nitec Pharma AG secures funding of CHF 24M from TVM and Deutsche Bank more...

29.09.2008 Medigene Clinical data for EndoTAG(TM)-1 to be presented at two further medical conferences (DVGS, UEGW) more...

21.09.2008 Coapt Sytems Launches FDA Cleared Novielle Voice(TM) For Restoration Of Voice Loss more...

16.09.2008 MediGene reports positive 12-month survival data for EndoTAG(TM)-1 from Phase II pancreatic cancer study more...

More news